Brief: Abionyx Pharma Gross Cash Position At EUR 4.8 Mln At End-June

Abionyx Pharma SA

05/08/2021 18:20

Aug 5 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * GROSS CASH POSITION OF €4.8 MILLION AT JUNE 30, 2021
    * LAUNCH OF THE PHASE 2A CLINICAL TRIAL, RACERS, EVALUATING CER-001 IN THE
PREVENTION OF ACUTE KIDNEY INJURY IN ICU PATIENTS WITH SEPTICEMIA
    * RECEIPT OF POSITIVE OPINION FROM EMA WITHIN THE FRAMEWORK OF THE ORPHAN
DRUG
DESIGNATION PROCESS FOR CER-001 FOR THE RARE DISEASE LCAT DEFICIENCY
    * DURING H2, ABIONYX PHARMA INTENDS TO PURSUE THE CLINICAL AND OPERATIONAL
DEVELOPMENT OF CER-001, WHOSE ENTIRE VALUE CHAIN IS NOW UNDER THE COMPANY'S FULL
CONTROL THANKS TO ITS STRATEGIC PRODUCTION AGREEMENT

Source text for Eikon:  ID:nNDL73cqBn 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))